Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells.

Wobser M, Weber A, Glunz A, Tauch S, Seitz K, Butelmann T, Hesbacher S, Goebeler M, Bartz R, Kohlhof H, Schrama D, Houben R.

J Hematol Oncol. 2019 Mar 18;12(1):30. doi: 10.1186/s13045-019-0719-4.

2.

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.

Pinkerneil M, Hoffmann MJ, Kohlhof H, Schulz WA, Niegisch G.

Target Oncol. 2016 Dec;11(6):783-798.

3.

Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.

Zhijun H, Shusheng W, Han M, Jianping L, Li-Sen Q, Dechun L.

Tumour Biol. 2016 Aug;37(8):10257-67. doi: 10.1007/s13277-016-4868-6. Epub 2016 Feb 1.

PMID:
26831668
4.

Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.

Rozati S, Cheng PF, Widmer DS, Fujii K, Levesque MP, Dummer R.

Clin Cancer Res. 2016 Apr 15;22(8):2020-31. doi: 10.1158/1078-0432.CCR-15-1435. Epub 2015 Dec 9.

5.

Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.

Singh MM, Manton CA, Bhat KP, Tsai WW, Aldape K, Barton MC, Chandra J.

Neuro Oncol. 2011 Aug;13(8):894-903. doi: 10.1093/neuonc/nor049. Epub 2011 Jun 8.

6.
7.

4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.

Fu M, Wan F, Li Z, Zhang F.

Biochem Biophys Res Commun. 2016 Mar 4;471(2):267-73. doi: 10.1016/j.bbrc.2016.01.030. Epub 2016 Jan 8.

PMID:
26773495
8.

Effects of novel HDAC inhibitors on urothelial carcinoma cells.

Kaletsch A, Pinkerneil M, Hoffmann MJ, Jaguva Vasudevan AA, Wang C, Hansen FK, Wiek C, Hanenberg H, Gertzen C, Gohlke H, Kassack MU, Kurz T, Schulz WA, Niegisch G.

Clin Epigenetics. 2018 Jul 31;10(1):100. doi: 10.1186/s13148-018-0531-y.

9.

The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, Hodges E, Vermeer M, Packham G.

Br J Pharmacol. 2011 Apr;162(7):1590-602. doi: 10.1111/j.1476-5381.2010.01188.x.

10.

Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.

Duan YC, Ma YC, Qin WP, Ding LN, Zheng YC, Zhu YL, Zhai XY, Yang J, Ma CY, Guan YY.

Eur J Med Chem. 2017 Nov 10;140:392-402. doi: 10.1016/j.ejmech.2017.09.038. Epub 2017 Sep 21.

PMID:
28987602
11.

LSD1 Substrate Binding and Gene Expression Are Affected by HDAC1-Mediated Deacetylation.

Nalawansha DA, Pflum MK.

ACS Chem Biol. 2017 Jan 20;12(1):254-264. doi: 10.1021/acschembio.6b00776. Epub 2016 Dec 15.

12.

Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells.

Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE.

Breast Cancer Res Treat. 2012 Feb;131(3):777-89. doi: 10.1007/s10549-011-1480-8. Epub 2011 Mar 31.

13.

Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.

Li LH, Zhang PR, Cai PY, Li ZC.

Biomed Pharmacother. 2016 Aug;82:161-6. doi: 10.1016/j.biopha.2016.04.053. Epub 2016 May 9.

PMID:
27470351
15.

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.

J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.

PMID:
26314218
16.

LSD1 regulates pluripotency of embryonic stem/carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16.

Yin F, Lan R, Zhang X, Zhu L, Chen F, Xu Z, Liu Y, Ye T, Sun H, Lu F, Zhang H.

Mol Cell Biol. 2014 Jan;34(2):158-79. doi: 10.1128/MCB.00631-13. Epub 2013 Nov 4.

17.

SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.

Nihal M, Ahmad N, Wood GS.

Cell Cycle. 2014;13(4):632-40. doi: 10.4161/cc.27523. Epub 2013 Dec 16. Erratum in: Cell Cycle. 2015;14(8):1337.

PMID:
24343700
18.

Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells.

Li Y, Tian X, Sui CG, Jiang YH, Liu YP, Meng FD.

Biomed Pharmacother. 2016 Aug;82:498-508. doi: 10.1016/j.biopha.2016.04.070. Epub 2016 Jun 2.

PMID:
27470390
19.

Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.

Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y.

Carcinogenesis. 2013 Jun;34(6):1196-207. doi: 10.1093/carcin/bgt033. Epub 2013 Jan 25.

20.

Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.

von Tresckow B, Sayehli C, Aulitzky WE, Goebeler ME, Schwab M, Braz E, Krauss B, Krauss R, Hermann F, Bartz R, Engert A.

Eur J Haematol. 2019 Feb;102(2):163-173. doi: 10.1111/ejh.13188. Epub 2019 Jan 7.

PMID:
30347469

Supplemental Content

Support Center